Results 1 to 10 of about 22,136 (209)

Pumpkin seed ethanolic extract protects against escitalopram-induced reproductive toxicity in male mice

Asian Pacific Journal of Reproduction, 2023
Objective: To investigate the protective role of pumpkin seed ethanolic extract against escitalopram-induced reproductive toxicity in male mice. Methods: Swiss albino male mice were randomly divided into five groups with six mice in each group.
Agrawal Karuna, Shahani Lata, Bhatnagar Pradeep   +2 more
doaj   +2 more sources

After 25 Years of Experience: What Do We Know About Escitalopram? [PDF]

Psychiatry and Clinical Psychopharmacology
Escitalopram, the S-enantiomer of racemic citalopram, is one of the most widely prescribed selective serotonin reuptake inhibitors (SSRIs) for the treatment of depressive and anxiety disorders. Owing to its high selectivity for the serotonin transporter (
Gözde Çolak, Ali Saffet Gönül
doaj   +2 more sources

Therapeutic effects of exercise-accompanied escitalopram on synaptic potency and long-term plasticity in the hippocampal CA1 area in rats under chronic restraint stress [PDF]

Iranian Journal of Basic Medical Sciences, 2022
Objective(s): Administration of antidepressants and exercise are among the therapeutic approaches to chronic stress. Therefore, this study compared the therapeutic effects of different doses of escitalopram, exercise, and exercise-accompanied ...
Mahshid Zamani, Maryam Radahmadi, Parham Reisi   +2 more
doaj   +1 more source

Comparative efficacy and safety of escitalopram, desvenlafaxine, and vortioxetine in the acute treatment of anxious depression: A randomized rater-blinded, 6-week clinical trial

European Psychiatry, 2022
Introduction This study is about the clinical uses of three antidepressants( escitalopram, desvenlafaxine, vortioxetine) in the treatment of anxioun depression. Objectives The purpose of this study was to compare the efficacy and safety of escitalopram,
K.-S. Oh, S.W. Jeon
doaj   +1 more source

Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis

BMC Psychiatry, 2023
Background Escitalopram is selective serotonin reuptake inhibitors (SSRIs) and one of the most commonly prescribed newer antidepressants (ADs) worldwide.
Juntao Yin, Xiaoyong Song, Chaoyang Wang, Xuhong Lin, Mingsan Miao   +4 more
doaj   +1 more source

Generic escitalopram initiation and substitution among Medicare beneficiaries: A new user cohort study.

PLoS ONE, 2020
OBJECTIVES:To examine patterns of generic escitalopram initiation and substitution among Medicare beneficiaries. METHODS:This retrospective new user cohort used a 5% random sample of 2013-2015 Medicare administrative claims data. Fee-for-service Medicare
Chao Li, Li Chen, Nan Huo, Ahmed Ullah Mishuk, Richard A Hansen, Ilene Harris, Zippora Kiptanui, Zhong Wang, Jingjing Qian   +8 more
doaj   +1 more source

Randomized and parallel-group study of cost-effectiveness analysis of escitalopram and desvenlafaxine in moderate-to-severe depression

National Journal of Physiology, Pharmacy and Pharmacology, 2023
Background: Cost-effectiveness analysis (CEA) measures costs and outcomes in monetary terms, it can be used to compare net benefits of all types of interventions.
Girish K, Moulya Nagaraj, Pavithra M S, Jyothi R, Lakshmi Pandith   +4 more
doaj   +1 more source

Spatio-temporal dynamics of EEG features during sleep in major depressive disorder after treatment with escitalopram: a pilot study

BMC Psychiatry, 2020
Background Previous studies have shown escitalopram is related to sleep quality. However, effects of escitalopram on dynamics of electroencephalogram (EEG) features especially during different sleep stages have not been reported.
Li Wu, Xue-Qin Wang, Yong Yang, Teng-Fei Dong, Ling Lei, Qi-Qi Cheng, Su-Xia Li   +6 more
doaj   +1 more source

Vortioxetine as a potential alternative for patients with escitalopram‐induced jitteriness/anxiety syndrome: A report of three cases

PCN Reports, 2023
Background Jitteriness/anxiety syndrome is a recognized adverse effect observed during the initiation or change of dose in antidepressant treatment. Managing patients who develop this syndrome remains a challenge.
Kaoru Arai, Mari Nonaka, Shoko Shimada, Masayuki Nakamura   +3 more
doaj   +1 more source

Systematic review and meta-analysis on the therapeutic reference range for escitalopram: Blood concentrations, clinical effects and serotonin transporter occupancy

Frontiers in Psychiatry, 2022
IntroductionA titration within a certain therapeutic reference range presupposes a relationship between the blood concentration and the therapeutic effect of a drug. However, this has not been systematically investigated for escitalopram.
Luzie Eichentopf, Christoph Hiemke, Christoph Hiemke, Andreas Conca, Andreas Conca, Jan Engelmann, Manfred Gerlach, Manfred Gerlach, Ursula Havemann-Reinecke, Ursula Havemann-Reinecke, Gudrun Hefner, Gudrun Hefner, Vincenzo Florio, Maxim Kuzin, Maxim Kuzin, Klaus Lieb, Margareta Reis, Margareta Reis, Thomas G. Riemer, Alessandro Serretti, Georgios Schoretsanitis, Georgios Schoretsanitis, Georgios Schoretsanitis, Georgios Schoretsanitis, Gerald Zernig, Gerald Zernig, Gerald Zernig, Gerhard Gründer, Gerhard Gründer, Xenia M. Hart, Xenia M. Hart   +30 more
doaj   +1 more source